Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Polyuria-polydipsia syndrome (thirst and passing large volumes of urine) in adults

Endocrinology and metabolism · Symptom or situation · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: Central diabetes insipidus: about 1 case per 25 000 people [1]

Initial work-up: confirm polyuria and rule out common causes

Urine tests

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Also consider

Do not order

Confirmed hypotonic polyuria without obvious cause: specialist advice

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (13)
  1. Tomkins M, Lawless S, Martin-Grace J, Sherlock M, Thompson CJ. Diagnosis and Management of Central Diabetes Insipidus in Adults. J Clin Endocrinol Metab. 2022;107(10):2701-15.
  2. Flynn K, Hatfield J, Brown K, Vietor N, Hoang T. Central and nephrogenic diabetes insipidus: updates on diagnosis and management. Front Endocrinol (Lausanne). 2024;15:1479764.
  3. ANSM, Base de données publique des médicaments. Résumé des caractéristiques du produit HOLOXAN 1000 mg (ifosfamide), poudre pour solution injectable, rubrique 4.8 (mise à jour du 21/05/2026), consulté le 12/10/2026.
  4. Marques P, Gunawardana K, Grossman A. Transient diabetes insipidus in pregnancy. Endocrinol Diabetes Metab Case Rep. 2015;2015:150078 (rapport de cas avec revue de la littérature).
  5. Working Group for Renaming Diabetes Insipidus ; Arima H, Cheetham T, Christ-Crain M, et al. Changing the name of diabetes insipidus: a position statement of The Working Group for Renaming Diabetes Insipidus. Endocr Connect. 2022;11(11):e220378 (publication simultanée dans plusieurs revues).
  6. American Diabetes Association Professional Practice Committee. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S27-S49.
  7. Bundesärztekammer (BÄK), Kassenärztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Nationale VersorgungsLeitlinie Typ-2-Diabetes, Langfassung, Version 3.0, 2023.
  8. Royal Australian College of General Practitioners, Diabetes Australia. Management of type 2 diabetes: a handbook for general practice. Novembre 2024, mis à jour en août 2025 : chapitre « Defining and diagnosing type 2 diabetes ».
  9. Baldeweg SE, Ball S, Brooke A, et al. Society for Endocrinology Clinical Guidance: Inpatient management of cranial diabetes insipidus. Endocr Connect. 2018;7(7):G8-G11.
  10. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1577 (HbA1c).
  11. Winzeler B, Cesana-Nigro N, Refardt J, et al. Arginine-stimulated copeptin measurements in the differential diagnosis of diabetes insipidus: a prospective diagnostic study. Lancet. 2019;394(10198):587-595.
  12. Refardt J, Atila C, Chifu I, et al. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023;389(20):1877-1887.
  13. Royal United Hospitals Bath NHS Foundation Trust, Clinical Biochemistry Department. Investigation of Diabetes Insipidus using Copeptin. Protocole DIAB-ENDO-020, version 4, 4 juin 2024.